Plasma dopamine beta hydroxylase activity in chronic schizophrenic patients tested with single dose of 2-bromo-alpha ergocriptine (Parlodel).
Plasma dopamine beta hydroxylase (D.B.H) activity was measured in 6 chronic schizophrenic patients. Treated with phenothiazine and butyrophenone derivatives after administering a single dose of bromocriptine (7,5 mg) orally, and compared to a matched group of 6 chronic treated schizophrenic patients without bromocriptine loading, and to a control matched group loaded with 7.5 mg of bromocriptine. A significant difference was observed in D.B.H. plasma levels of the schizophrenic patients group who received bromocriptine, by comparison with the other two control groups.
D000284:Administration, Oral; D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002908:Chronic Disease; D004299:Dopamine beta-Hydroxylase / Q000097:blood*; D006801:Humans; D008297:Male; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy / Q000201:enzymology*; D013268:Stimulation, Chemical
D011954:Receptors, Dopamine; D001971:Bromocriptine; D004299:Dopamine beta-Hydroxylase